In Reply

This report aims to describe complex regional pain syndrome (CRPS) type I and type II. CRPS describes a spectrum of painful conditions that have a common presentation, including pain that is disproportionate to the initiating injury or instigating event. Both CRPS type I and type II have a hallmark of allodynia, severe hyperalgesia, edema and skin changes, and abnormal alterations in sudomotor and vasomotor function. CRPS type I was formally identified as reflex sympathetic dystrophy. CRPS type II is a new term for what was formally described as causalgia. The difference between the two is mainly in the type of inciting event rather than clinical presentation: type I does not include obvious nerve injury, whereas type II CRPS occurs with documented nerve injury. CRPS can occur in both the acute setting and as an exacerbation or change in existing chronic pain. Symptoms of CRPS can occur from a wide range of insults or injuries, such as ankle sprain, bug bite, an operation, or after casting. Similarly, the diagnostic criteria for CRPS type I and type II point to a spectrum of clinical and symptom findings, further emphasizing the varied nature and spectrum of the syndrome. No single standard test is available for its diagnosis. Clinical and exam findings are critical in forming the diagnosis for CRPS type I and type II, and there is a clear pattern of pain that needs to be identified early despite the possibility that all criteria may not have been met for diagnosis. Clinical treatment of patients with CRPS and those that may not fit all criteria for CRPS should emphasize functional restoration, pain abatement using appropriate pharmacological medications and interventional treatment, and psychological therapy. Patients with CRPS need a customized approach to their treatment, and care must be taken to address these needs early to provide the best outcomes. CRPS can progress rapidly if there is a failure in specialized functional restoration and rest therapeutic treatment to help musculoskeletal function.

Prognostic value of triple phase bone scanning for reflex sympathetic dystrophy in hemiplegia.

Complex regional pain syndrome (CRPS) is a painful and disabling condition that usually manifests in response to trauma or surgery and is associated with significant pain and disability. CRPS can be classified into two types: type I (CRPS I) in which a specific nerve lesion has not been identified and type II (CRPS II) where there is an identifiable nerve lesion. Guidelines recommend the inclusion of a variety of physiotherapy interventions as part of the multimodal treatment of people with CRPS. This is the first update of the review originally published in Issue 2, 2016. To determine the effectiveness of physiotherapy interventions for treating pain and disability associated with CRPS types I and II in adults. For this update we searched CENTRAL (the Cochrane Library), MEDLINE, Embase, CINAHL, PsycINFO, LILACS, PEDro, Web of Science, DARE and Health Technology Assessments from February 2015 to July 2021 without language restrictions, we searched the reference lists of included studies and we contacted an expert in the field. We also searched additional online sources for unpublished trials and trials in progress. We included randomised controlled trials (RCTs) of physiotherapy interventions compared with placebo, no treatment, another intervention or usual care, or other physiotherapy interventions in adults with CRPS I and II. Primary outcomes were pain intensity and disability. Secondary outcomes were composite scores for CRPS symptoms, health-related quality of life (HRQoL), patient global impression of change (PGIC) scales and adverse effects. Two review authors independently screened database searches for eligibility, extracted data, evaluated risk of bias and assessed the certainty of evidence using the GRADE system. We included 16 new trials (600 participants) along with the 18 trials from the original review totalling 34 RCTs (1339 participants). Thirty-three trials included participants with CRPS I and one trial included participants with CRPS II. Included trials compared a diverse range of interventions including physical rehabilitation, electrotherapy modalities, cortically directed rehabilitation, electroacupuncture and exposure-based approaches. Most interventions were tested in small, single trials. Most were at high risk of bias overall (27 trials) and the remainder were at 'unclear' risk of bias (seven trials). For all comparisons and outcomes where we found evidence, we graded the certainty of the evidence as very low, downgraded due to serious study limitations, imprecision and inconsistency. Included trials rarely reported adverse effects. Physiotherapy compared with minimal care for adults with CRPS I One trial (135 participants) of multimodal physiotherapy, for which pain data were unavailable, found no between-group differences in pain intensity at 12-month follow-up. Multimodal physiotherapy demonstrated a small between-group improvement in disability at 12 months follow-up compared to an attention control (Impairment Level Sum score, 5 to 50 scale; mean difference (MD) -3.7, 95% confidence interval (CI) -7.13 to -0.27) (very low-certainty evidence). Equivalent data for pain were not available. Details regarding adverse events were not reported. Physiotherapy compared with minimal care for adults with CRPS II We did not find any trials of physiotherapy compared with minimal care for adults with CRPS II. The evidence is very uncertain about the effects of physiotherapy interventions on pain and disability in CRPS. This conclusion is similar to our 2016 review. Large-scale, high-quality RCTs with longer-term follow-up are required to test the effectiveness of physiotherapy-based interventions for treating pain and disability in adults with CRPS I and II.

Isolated Gonococcal Extensor Tenosynovitis

Electrocardiographic features of patients with COVID-19: One year of unexpected manifestations

Capnocytophaga canimorsus Sepsis Following a Minor Dog Bite to the Finger: Case Report

Idiopathic Systemic Capillary Leak Syndrome Preceding Diagnosis of Infiltrating Lobular Carcinoma of the Breast With Quiescence During Neoadjuvant Chemotherapy

Transforming growth factor beta (TGF-beta) and related growth factors are essential regulators of embryogenesis and tissue homeostasis. The signaling pathways mediated by their receptors and Smad proteins are precisely modulated by various means. Xenopus BAMBI (bone morphogenic protein (BMP) and activin membrane-bound inhibitor) has been shown to function as a general negative regulator of TGF-beta/BMP/activin signaling. Here, we provide evidence that human BAMBI (hBAMBI), like its Xenopus homolog, inhibits TGF-beta- and BMP-mediated transcriptional responses as well as TGF-beta-induced R-Smad phosphorylation and cell growth arrest, whereas knockdown of endogenous BAMBI enhances the TGF-beta-induced reporter expression. Mechanistically, in addition to interfering with the complex formation between the type I and type II receptors, hBAMBI cooperates with Smad7 to inhibit TGF-beta signaling. hBAMBI forms a ternary complex with Smad7 and the TGF-beta type I receptor ALK5/TbetaRI and inhibits the interaction between ALK5/TbetaRI and Smad3, thus impairing Smad3 activation. These findings provide a novel insight to understand the molecular mechanism underlying the inhibitory effect of BAMBI on TGF-beta signaling.

Complex regional pain syndrome (CRPS), formerly known as “reflex sympathetic dystrophy” and “causalgia”, is a syndrome that refers to a chronic pain condition associated with autonomic disturbances of vasomotor and sudomotor origin (Birklein et al., 1998), along with trophic skin changes and patchy demineralization of the bones (Poplawski et al., 1983). CRPS is classified into type I and II; the former can develop after minor or remote trauma like stroke, spinal cord injury or myocardial infarction (Wasner et al., 1998); the latter can develop after a large peripheral nerve lesion (Janig & Baron, 2003). The syndrome corresponding to what was formerly described as reflex sympathetic dystrophy is now termed as CRPS type I; causalgia is now termed as CRPS type II (Merseky & Bogduk, 1994). Although the mechanism of CRPS has not been elucidated yet, recent studies indicate that it is a complex disorder that involves both the central and peripheral nervous systems (Daemen et al., 1998; Huygen et al., 2001). CRPS pathogenesis is heterogeneous and complex, which makes its treatment challenging. Pharmacological therapies of CRPS include anti-inflammatory drugs, systemic corticosteroid (Kingery, 1997), antidepressants, opioid (Mackey & Feinberg, 2007), anticonvulsants, free-radical scavengers, vasodilatory medication (Perez et al., 2010) and even bisphosphonate agents (Adami et al., 1997; Manicourt et al., 2004; Robinson et al., 2004; Varenna et al., 2000). In addition, vitamin C is recommended to prevent the occurrence of CRPS type I after wrist fracture (Perez et al., 2010). However, there is yet no single pharmacological agent or treatment algorithm that can resolve all of its heterogenic features. The efficacy for most pharmacological agents remains largely empirical, with the exception of bisphosphonate agents, which are the only agents with proven efficacy for CRPS based on multiple controlled trials (Adami et al., 1997; Brunner et al., 2009; Mackey & Feinberg, 2007;, Manicourt et al., 2004, Robinson et al., 2004, Varenna et al., 2000). In order to understand how these bisphosphonate agents are useful in CRPS treatment, it is imperative to understand the pathogenesis of patchy osteoporosis in CRPS. This section will first review CRPS, then it will introduce the different experimental animal models. Finally this section will discuss the different treatment agents that have been studied for patchy osteoporosis.

SummaryIntroduction: Complex regional pain syndrome (CRPS) is a relatively rare disorder, but one that is extremely serious for the affected patient. It usually occurs in the area distal to a primary limb injury. The clinical symptoms and the pain are out of all proportion to the inciting event and in approximately 10 % of CRPS patients, there is no triggering event at all. CRPS leads to long-term disability and high treatment and follow-up costs In about half of those affected.Clinical symptoms: Two forms exist. In CRPS type 1, no nerve lesions are present, whereas in CRPS type 2, injury has occurred to a nerve or the main branch of a nerve. However, in terms of their clinical course, there is no difference between the two forms. Approximately 90 % of all cases involve CRPS type 1, formerly known as “Sudeck’s atrophy”. The cardinal symptom is pain. In addition, trophic disturbances, such as swelling, local skin discolouration or asymmetric skin temperatures, can also occur. Impaired mobility and function of the affected limb also occur frequently and are very difficult to treat.Diagnosis: Initially, it can be difficult to distinguish between CRPS and a normal post-traumatic course. Subsequently, the severe symptoms are out of all proportion to the inciting event. The diagnosis of CRPS is based mainly on the clinical symptoms. The Budapest criteria help to confirm the diagnosis.Therapy: Early and interdisciplinary rehabilitation is of crucial importance in CRPS treatment. Occupational therapy and physiotherapy are supplemented by good analgesic management and psychological support, if required. Analgesia should be based on the WHO pain ladder. Methadone is of proven efficacy in cases of severe hyperalgesia and gabapentin or pregabalin are used to treat refractory pain. Bisphosphonates have shown a good analgesic effect, particularly in patients with confirmed bone lesions. Chronic oedema and inflammation may require short-term steroid administration. A further clinical goal is the avoidance of sequelae, such as osteoporosis. Patients with suspected CRPS should be referred to a multidisciplinary treatment team, preferably one with considerable experience in treating this clinical presentation. One physician should coordinate the patient’s treatment. The earlier the treatment is started, the better the prognosis.

Non-prescription medication providers fight the opioid crisis with use of diagnostic testing

The multipotentiality and self-renewal ability of stem cells are controlled by intrinsic genetic pathways that are subject to regulation by extrinsic signals emanating from the stem cell niche. The stem cell niche provides a microenvironment composed of cellular structures or extracellular matrix in which stem cells are maintained as undifferentiated (1Li L. Xie T. Annu. Rev. Cell Dev. Biol. 2005; 21: 605-631Crossref PubMed Scopus (942) Google Scholar, 2Lin H. Nat. Rev. Genet. 2002; 3: 931-940Crossref PubMed Scopus (305) Google Scholar, 3Scadden D.T. Nature. 2006; 441: 1075-1079Crossref PubMed Scopus (1508) Google Scholar, 4Spradling A. Drummond-Barbosa D. Kai T. Nature. 2001; 414: 98-104Crossref PubMed Scopus (1215) Google Scholar, 5Watt F.M. Hogan B.L. Science. 2000; 287: 1427-1430Crossref PubMed Scopus (1474) Google Scholar, 6Fuchs E. Tumbar T. Guasch G. Cell. 2004; 116: 769-778Abstract Full Text Full Text PDF PubMed Scopus (1481) Google Scholar). The concept of "the stem cell niche" was first proposed in studies of the HSC 2The abbreviations used are:HSChematopoietic stem cellGSCgerm line stem cellBMbone marrowCARCXCL12-abundant reticularCBscystoblastsESCescort stem cellCPscyst progenitorsAng-1angiopoietin-1.2The abbreviations used are:HSChematopoietic stem cellGSCgerm line stem cellBMbone marrowCARCXCL12-abundant reticularCBscystoblastsESCescort stem cellCPscyst progenitorsAng-1angiopoietin-1. (7Schofield R. Blood Cells. 1978; 4: 7-25PubMed Google Scholar); however, in vivo evidence of its existence was first shown in the Drosophila GSC (8Cox D.N. Chao A. Baker J. Chang L. Qiao D. Lin H. Genes Dev. 1998; 12: 3715-3727Crossref PubMed Scopus (802) Google Scholar, 9King F.J. Lin H. Development (Camb.). 1999; 126: 1833-1844PubMed Google Scholar, 10Xie T. Spradling A.C. Science. 2000; 290: 328-330Crossref PubMed Scopus (620) Google Scholar). Over the past several years, there has been much progress made in identifying stem cell niches in different mammal tissues, including nerves, hair follicles, intestines, teeth, and BM (11Tumbar T. Guasch G. Greco V. Blanpain C. Lowry W.E. Rendl M. Fuchs E. Science. 2004; 303: 359-363Crossref PubMed Scopus (1631) Google Scholar, 12Yen T.H. Wright N.A. Stem Cell Rev. 2006; 2: 203-212Crossref PubMed Scopus (227) Google Scholar, 13Conover J.C. Notti R.Q. Cell Tissue Res. 2008; 331: 211-224Crossref PubMed Scopus (123) Google Scholar, 14Doetsch F. Curr. Opin. Genet. Dev. 2003; 13: 543-550Crossref PubMed Scopus (529) Google Scholar, 15Ohshima H. Nakasone N. Hashimoto E. Sakai H. Nakakura-Ohshima K. Harada H. Arch. Oral Biol. 2005; 50: 153-157Crossref PubMed Scopus (81) Google Scholar, 16Wilson A. Trumpp A. Nat. Rev. Immunol. 2006; 6: 93-106Crossref PubMed Scopus (1050) Google Scholar). In this review, our focus is on comparing Drosophila GSC niches and mouse HSC niches (two of the best characterized niches). By such comparison, we hope to provide some common principles of stem cell niches that will be useful in other tissue stem cell niche studies. hematopoietic stem cell germ line stem cell bone marrow CXCL12-abundant reticular cystoblasts escort stem cell cyst progenitors angiopoietin-1. hematopoietic stem cell germ line stem cell bone marrow CXCL12-abundant reticular cystoblasts escort stem cell cyst progenitors angiopoietin-1. In recent years, remarkable progress has been made in the identification and characterization of the stem cell niches in invertebrate systems (10Xie T. Spradling A.C. Science. 2000; 290: 328-330Crossref PubMed Scopus (620) Google Scholar, 17Tulina N. Matunis E. Science. 2001; 294: 2546-2549Crossref PubMed Scopus (506) Google Scholar, 18Kiger A.A. Jones D.L. Schulz C. Rogers M.B. Fuller M.T. Science. 2001; 294: 2542-2545Crossref PubMed Scopus (538) Google Scholar, 19Lin H. Spradling A.C. Dev. Genet. 1995; 16: 6-12Crossref PubMed Scopus (180) Google Scholar, 20Crittenden S.L. Bernstein D.S. Bachorik J.L. Thompson B.E. Gallegos M. Petcherski A.G. Moulder G. Barstead R. Wickens M. Kimble J. Nature. 2002; 417: 660-663Crossref PubMed Scopus (337) Google Scholar, 21Mandal L. Martinez-Agosto J.A. Evans C.J. Hartenstein V. Banerjee U. Nature. 2007; 446: 320-324Crossref PubMed Scopus (220) Google Scholar, 22Krzemien J. Dubois L. Makki R. Meister M. Vincent A. Crozatier M. Nature. 2007; 446: 325-328Crossref PubMed Scopus (246) Google Scholar). In studies of GSCs in Drosophila, the ovary and testis provide relatively simple but elegant anatomic structures with few cell types and unique stem cell markers. These advantages facilitated identification of the cellular components of the stem cell niche and definition of the molecular basis of physical interaction between stem cells and their niches (23Song X. Xie T. Proc. Natl. Acad. Sci. U. S. A. 2002; 99: 14813-14818Crossref PubMed Scopus (184) Google Scholar, 24Yamashita Y.M. Jones D.L. Fuller M.T. Science. 2003; 301: 1547-1550Crossref PubMed Scopus (595) Google Scholar) and revealed key niche signals involved in stem cell regulation (18Kiger A.A. Jones D.L. Schulz C. Rogers M.B. Fuller M.T. Science. 2001; 294: 2542-2545Crossref PubMed Scopus (538) Google Scholar, 25LaFever L. Drummond-Barbosa D. Science. 2005; 309: 1071-1073Crossref PubMed Scopus (248) Google Scholar, 26Szakmary A. Cox D.N. Wang Z. Lin H. Curr. Biol. 2005; 15: 171-178Abstract Full Text Full Text PDF PubMed Scopus (124) Google Scholar, 27Xie T. Spradling A.C. Cell. 1998; 94: 251-260Abstract Full Text Full Text PDF PubMed Scopus (530) Google Scholar, 28Yamashita Y.M. Fuller M.T. Jones D.L. J. Cell Sci. 2005; 118: 665-672Crossref PubMed Scopus (166) Google Scholar, 29Parisi M.J. Lin H. Cell Res. 1998; 8: 15-21Crossref PubMed Scopus (38) Google Scholar, 30King F.J. Szakmary A. Cox D.N. Lin H. Mol. Cell. 2001; 7: 497-508Abstract Full Text Full Text PDF PubMed Scopus (126) Google Scholar, 31Wang Z. Lin H. Science. 2004; 303: 2016-2019Crossref PubMed Scopus (197) Google Scholar). In the murine hematopoietic system, HSCs have been well defined (32Spangrude G.J. Heimfeld S. Weissman I.L. Science. 1988; 241: 58-62Crossref PubMed Scopus (2226) Google Scholar, 33Weissman I.L. Science. 2000; 287: 1442-1446Crossref PubMed Scopus (713) Google Scholar), but identification of the HSC niches is just beginning. This search has been hampered by the complexity of the BM structure and cellular components and by the lack of unique HSC markers or distinctive characteristics of BM stromal cells. Two HSC niches have been proposed in murine BM, an osteoblastic niche and a vascular niche, in which osteoblasts and vascular endothelial cells have been demonstrated as major components, respectively (34Zhang J. Niu C. Ye L. Huang H. He X. Tong W.G. Ross J. Haug J. Johnson T. Feng J.Q. Harris S. Wiedemann L.M. Mishina Y. Li L. Nature. 2003; 425: 836-841Crossref PubMed Scopus (2385) Google Scholar, 35Calvi L.M. Adams G.B. Weibrecht K.W. Weber J.M. Olson D.P. Knight M.C. Martin R.P. Schipani E. Divieti P. Bringhurst F.R. Milner L.A. Kronenberg H.M. Scadden D.T. Nature. 2003; 425: 841-846Crossref PubMed Scopus (2799) Google Scholar, 36Arai F. Hirao A. Ohmura M. Sato H. Matsuoka S. Takubo K. Ito K. Koh G.Y. Suda T. Cell. 2004; 118: 149-161Abstract Full Text Full Text PDF PubMed Scopus (1540) Google Scholar, 37Nilsson S.K. Johnston H.M. Whitty G.A. Williams B. Webb R.J. Denhardt D.T. Bertoncello I. Bendall L.J. Simmons P.J. Haylock D.N. Blood. 2005; 106: 1232-1239Crossref PubMed Scopus (605) Google Scholar, 38Heissig B. Rafii S. Akiyama H. Ohki Y. Sato Y. Rafael T. Zhu Z. Hicklin D.J. Okumura K. Ogawa H. Werb Z. Hattori K. J. Exp. Med. 2005; 202: 739-750Crossref PubMed Scopus (195) Google Scholar, 39Moore K.A. Curr. Opin. Hematol. 2004; 11: 107-111Crossref PubMed Scopus (56) Google Scholar, 40Taichman R.S. Blood. 2005; 105: 2631-2639Crossref PubMed Scopus (469) Google Scholar, 41Kiel M.J. Yilmaz O.H. Iwashita T. Terhorst C. Morrison S.J. Cell. 2005; 121: 1109-1121Abstract Full Text Full Text PDF PubMed Scopus (2414) Google Scholar). A recent study suggested that a population of reticular cells named CAR cells, which express a high level of CXCL12 (also known as stromal cell-derived factor-1 or pre-B cell growth-stimulating factor), are in contact with HSCs in both osteoblastic and vascular niches (42Sugiyama T. Kohara H. Noda M. Nagasawa T. Immunity. 2006; 25: 977-988Abstract Full Text Full Text PDF PubMed Scopus (1693) Google Scholar). Drosophila ovary and testis provide attractive models for stem cell niche studies. In Drosophila ovary, cap cells, a specific type of somatic cell located at the tip of the germarium in the ovary, function as the niche for GSCs. An E-cadherin/β-catenin-formed cell-cell adhesion junction mediates the physical interaction between GSCs and their niche cells (23Song X. Xie T. Proc. Natl. Acad. Sci. U. S. A. 2002; 99: 14813-14818Crossref PubMed Scopus (184) Google Scholar, 46Song X. Zhu C.H. Doan C. Xie T. Science. 2002; 296: 1855-1857Crossref PubMed Scopus (389) Google Scholar), ensuring stem cell control by niche signals. Normally, asymmetric division of stem cells results in two daughter cells with different fates: one daughter cell attaches to the niche and is maintained as a stem cell (self-renewal), whereas the other daughter cell leaves the niche and develops into a cystoblast (1Li L. Xie T. Annu. Rev. Cell Dev. Biol. 2005; 21: 605-631Crossref PubMed Scopus (942) Google Scholar, 4Spradling A. Drummond-Barbosa D. Kai T. Nature. 2001; 414: 98-104Crossref PubMed Scopus (1215) Google Scholar). CBs undergo four incomplete cell divisions to form an interconnected 2–16-cell germ line cyst. In addition to the GSC, another type of cell called the ESC also attaches to cap cells interspersed between the GSCs. Together with cap cells, ESCs encapsulate GSCs to separate GSCs from their differentiated daughter cells. When the GSCs divide and detach from the niche to produce CBs and cyst cells, the ESCs also proliferate and differentiate to produce more escort cells. The escort cells expand and continue to encapsulate CBs and cysts during the process of cyst formation and are finally replaced by follicle cells after the 16-cell germ line cyst stage (Fig. 1a). Interestingly, the newly formed cysts (prior to the eight-cell cyst stage, while still encapsulated by the escort cell) can revert to the stem cell state under certain circumstances, suggesting that they may still retain (albeit limited) stem cell properties (47Kai T. Spradling A. Nature. 2004; 428: 564-569Crossref PubMed Scopus (267) Google Scholar). A similar niche is also found in Drosophila testis and is composed of hub cells located at the end of the testis (48Le Bras S. Van Doren M. Dev. Biol. 2006; 294: 92-103Crossref PubMed Scopus (96) Google Scholar). Male GSCs surrounding the hub cells are interspersed with CPs (which are counterparts of ESCs in the ovary). Both GSCs and CPs are attached to the hub cells through an adhesion junction. Similar to ESCs in the ovary, proliferation and differentiation of CPs always accompany proliferation and differentiation of GSCs. CPs in the testis produce cyst cells, which encapsulate the gonialblasts (the immediate daughters of male GSCs) during spermatogonium formation (Fig. 1b). The newly formed gonialblasts can also revert to stem cells under certain circumstances, resembling their counterpart cells (CBs and cysts) in the ovary (49Brawley C. Matunis E. Science. 2004; 304: 1331-1334Crossref PubMed Scopus (326) Google Scholar). The role of cap and hub cells in GSC regulation has been well studied, but the contribution of ESCs and their offspring in the ovary and CPs and their progeny in the testis to GSC self-renewal, proliferation, and differentiation is largely unknown. However, it is known that a dialogue between the two types of cells is required for the coordination during organogenesis (30King F.J. Szakmary A. Cox D.N. Lin H. Mol. Cell. 2001; 7: 497-508Abstract Full Text Full Text PDF PubMed Scopus (126) Google Scholar). Cap and hub cells provide an attachment point for anchoring GSCs to the niche; they also produce signals that inhibit differentiation but promote self-renewal of stem cells (17Tulina N. Matunis E. Science. 2001; 294: 2546-2549Crossref PubMed Scopus (506) Google Scholar). The stem cell niches in mammals are very complicated because of the complexity of cellular components of mammalian tissues, even though the mechanism for niche regulation is conserved from invertebrate to vertebrate. In mammals, BM tissue is composed of more than eight different hematopoietic cell lineages supported by a network of mesenchymal stromal cells and vascular endothelial cells. The two HSC niches, osteoblastic (34Zhang J. Niu C. Ye L. Huang H. He X. Tong W.G. Ross J. Haug J. Johnson T. Feng J.Q. Harris S. Wiedemann L.M. Mishina Y. Li L. Nature. 2003; 425: 836-841Crossref PubMed Scopus (2385) Google Scholar, 35Calvi L.M. Adams G.B. Weibrecht K.W. Weber J.M. Olson D.P. Knight M.C. Martin R.P. Schipani E. Divieti P. Bringhurst F.R. Milner L.A. Kronenberg H.M. Scadden D.T. Nature. 2003; 425: 841-846Crossref PubMed Scopus (2799) Google Scholar, 36Arai F. Hirao A. Ohmura M. Sato H. Matsuoka S. Takubo K. Ito K. Koh G.Y. Suda T. Cell. 2004; 118: 149-161Abstract Full Text Full Text PDF PubMed Scopus (1540) Google Scholar, 37Nilsson S.K. Johnston H.M. Whitty G.A. Williams B. Webb R.J. Denhardt D.T. Bertoncello I. Bendall L.J. Simmons P.J. Haylock D.N. Blood. 2005; 106: 1232-1239Crossref PubMed Scopus (605) Google Scholar, 38Heissig B. Rafii S. Akiyama H. Ohki Y. Sato Y. Rafael T. Zhu Z. Hicklin D.J. Okumura K. Ogawa H. Werb Z. Hattori K. J. Exp. Med. 2005; 202: 739-750Crossref PubMed Scopus (195) Google Scholar, 39Moore K.A. Curr. Opin. Hematol. 2004; 11: 107-111Crossref PubMed Scopus (56) Google Scholar, 40Taichman R.S. Blood. 2005; 105: 2631-2639Crossref PubMed Scopus (469) Google Scholar, 41Kiel M.J. Yilmaz O.H. Iwashita T. Terhorst C. Morrison S.J. Cell. 2005; 121: 1109-1121Abstract Full Text Full Text PDF PubMed Scopus (2414) Google Scholar, 50Balduino A. Hurtado S.P. Frazao P. Takiya C.M. Alves L.M. Nasciutti L.E. El-Cheikh M.C. Borojevic R. Cell Tissue Res. 2005; 319: 255-266Crossref PubMed Scopus (90) Google Scholar, 51Arai F. Hirao A. Suda T. Trends Cardiovasc. Med. 2005; 15: 75-79Crossref PubMed Scopus (66) Google Scholar, 52Adams G.B. Chabner K.T. Alley I.R. Olson D.P. Szczepiorkowski Z.M. Poznansky M.C. Kos C.H. Pollak M.R. Brown E.M. Scadden D.T. Nature. 2006; 439: 599-603Crossref PubMed Scopus (600) Google Scholar) and vascular (41Kiel M.J. Yilmaz O.H. Iwashita T. Terhorst C. Morrison S.J. Cell. 2005; 121: 1109-1121Abstract Full Text Full Text PDF PubMed Scopus (2414) Google Scholar, 53Kopp H.G. Avecilla S.T. Hooper A.T. Rafii S. Physiology. 2005; 20: 349-356Crossref PubMed Scopus (414) Google Scholar), are found in adult BM tissue. The vascular niche might also exist in fetal hematopoietic tissues such as yolk sac, aorta-gonad-mesonephros region, placenta, liver, and spleen (54Tavian M. Peault B. Exp. Hematol. 2005; 33: 1062-1069Abstract Full Text Full Text PDF PubMed Scopus (61) Google Scholar, 55Basto D. Trovisco V. Lopes J.M. Martins A. Pardal F. Soares P. Reis R.M. Acta Neuropathol. 2005; 109: 207-210Crossref PubMed Scopus (84) Google Scholar, 56Gekas C. Dieterlen-Lièvre F. Orkin S.H. Millola H.K.A. Dev. Cell. 2005; 8: 365-375Abstract Full Text Full Text PDF PubMed Scopus (504) Google Scholar) as well as in adult spleen and liver. Both niches may be critical for HSC self-renewal. Cooperation between these two niches might be required for maintaining normal hematopoietic homeostasis and re-establishing hematopoiesis after injury. Accumulated evidence supports the existence of an osteoblastic niche in BM. The concurrence of hematopoiesis and osteogenesis in BM suggests a close relationship between bone-forming cells and hematopoietic cells (57Patt H.M. Maloney M.A. Proc. Soc. Exp. Biol. Med. 1972; 140: 205-207Crossref PubMed Scopus (35) Google Scholar, 58Maloney M.A. Patt H.M. Proc. Soc. Exp. Biol. Med. 1975; 149: 94-97Crossref PubMed Scopus (12) Google Scholar). Early studies demonstrated that endosteal BM is more highly enriched with HSCs/progenitors compared with central BM (59Lord B.I. Testa N.G. Hendry J.H. Blood. 1975; 46: 65-72Crossref PubMed Google Scholar, 60Gong J.K. Science. 1978; 199: 1443-1445Crossref PubMed Scopus (195) Google Scholar). The facts that hematopoiesis recovery after myeloablative injury occurs on the endosteal bone surface (45Heissig B. Hattori K. Dias S. Friedrich M. Ferris B. Hackett N.R. Crystal R.G. Besmer P. Lyden D. Moore M.A. Werb Z. Rafii S. Cell. 2002; 109: 625-637Abstract Full Text Full Text PDF PubMed Scopus (1510) Google Scholar) and that the majority of HSCs/progenitors are distributed in the endosteal region after transplantation (61Nilsson S.K. Johnston H.M. Coverdale J.A. Blood. 2001; 97: 2293-2299Crossref PubMed Scopus (473) Google Scholar) support the importance of the endosteal BM microenvironment in HSC maintenance and regulation. Several genetically modulated mutant mouse models exhibit defects in hematopoiesis as a consequence of abnormal bone formation or remodeling, indicating the important role of osteoblasts in supporting HSCs in BM (62Deguchi K. Yagi H. Inada M. Yoshizaki K. Kishimoto T. Komori T. Biochem. Biophys. Res. Commun. 1999; 255: 352-359Crossref PubMed Scopus (49) Google Scholar, 63Ducy P. Zhang R. Geoffroy V. Ridall A.L. Karsenty G. Cell. 1997; 89: 747-754Abstract Full Text Full Text PDF PubMed Scopus (3630) Google Scholar, 64Gerber H.P. Vu T.H. Ryan A.M. Kowalski J. Werb Z. Ferrara N. Nat. Med. 1999; 5: 623-628Crossref PubMed Scopus (1707) Google Scholar, 65Nilsson S.K. Bertoncello I. Exp. Hematol. 1994; 22: 377-383PubMed Google Scholar, 66Begg S.K. Radley J.M. Pollard J.W. Chisholm O.T. Stanley E.R. Bertoncello I. J. Exp. Med. 1993; 177: 237-242Crossref PubMed Scopus (160) Google Scholar, 67Wang S. Wang Q. Crute B.E. Melnikova I.N. Keller S.R. Speck N.A. Mol. Cell. Biol. 1993; 13: 3324-3339Crossref PubMed Scopus (394) Google Scholar). Significant reduction in the number or functional disruption of osteoblasts leads to significant reduction in BM HSCs, and this often results in extramedullary hematopoiesis in the spleen (68Visnjic D. Kalajzic Z. Rowe D.W. Katavic V. Lorenzo J. Aguila H.L. Blood. 2004; 103: 3258-3264Crossref PubMed Scopus (598) Google Scholar). Additional trabecular bone formation and a corresponding increase in the number of osteoblasts in mice correlate with an increase in the number of BM HSCs (34Zhang J. Niu C. Ye L. Huang H. He X. Tong W.G. Ross J. Haug J. Johnson T. Feng J.Q. Harris S. Wiedemann L.M. Mishina Y. Li L. Nature. 2003; 425: 836-841Crossref PubMed Scopus (2385) Google Scholar, 35Calvi L.M. Adams G.B. Weibrecht K.W. Weber J.M. Olson D.P. Knight M.C. Martin R.P. Schipani E. Divieti P. Bringhurst F.R. Milner L.A. Kronenberg H.M. Scadden D.T. Nature. 2003; 425: 841-846Crossref PubMed Scopus (2799) Google Scholar). Moreover, osteoblastic cells support HSC self-renewal in in vitro culture (40Taichman R.S. Blood. 2005; 105: 2631-2639Crossref PubMed Scopus (469) Google Scholar) and enhance BM engraftment of HSCs in vivo when they are co-transplanted (69El-Badri N.S. Wang B.Y. Cherry Good R.A. Exp. Hematol. 1998; 26: 110-116PubMed Google Scholar) into recipient mice. Direct evidence of osteoblasts as the HSC niche has been provided in studies of several genetically modulated mouse models (35Calvi L.M. Adams G.B. Weibrecht K.W. Weber J.M. Olson D.P. Knight M.C. Martin R.P. Schipani E. Divieti P. Bringhurst F.R. Milner L.A. Kronenberg H.M. Scadden D.T. Nature. 2003; 425: 841-846Crossref PubMed Scopus (2799) Google Scholar, 36Arai F. Hirao A. Ohmura M. Sato H. Matsuoka S. Takubo K. Ito K. Koh G.Y. Suda T. Cell. 2004; 118: 149-161Abstract Full Text Full Text PDF PubMed Scopus (1540) Google Scholar, 68Visnjic D. Kalajzic Z. Rowe D.W. Katavic V. Lorenzo J. Aguila H.L. Blood. 2004; 103: 3258-3264Crossref PubMed Scopus (598) Google Scholar, 70Wilson A. Murphy M.J. Oskarsson T. Kaloulis K. Bettess M.D. Oser G.M. Pasche A.C. Knabenhans C. MacDonald H.R. Trumpp A. Genes Dev. 2004; 18: 2747-2763Crossref PubMed Scopus (587) Google Scholar, 71Katayama Y. Battista M. Kao W.M. Hidalgo A. Cell. 2006; Full Text Full Text PDF PubMed Scopus Google Scholar). is that osteoblasts function as the HSC niche; we found that a of osteoblasts that express a high level of function as a key of the osteoblastic niche (34Zhang J. Niu C. Ye L. Huang H. He X. Tong W.G. Ross J. Haug J. Johnson T. Feng J.Q. Harris S. Wiedemann L.M. Mishina Y. Li L. Nature. 2003; 425: 836-841Crossref PubMed Scopus (2385) Google Scholar). This is supported by in vitro functional studies that an increase in in cells BM stromal cell by or the ability of cells to support HSCs F. Hirao A. Ohmura M. Sato H. Matsuoka S. Takubo K. Ito K. Koh G.Y. Suda T. Cell. 2004; 118: 149-161Abstract Full Text Full Text PDF PubMed Scopus (1540) Google Scholar). The existence of an osteoblastic niche has also been in several other studies. and A. Murphy M.J. Oskarsson T. Kaloulis K. Bettess M.D. Oser G.M. Pasche A.C. Knabenhans C. MacDonald H.R. Trumpp A. Genes Dev. 2004; 18: 2747-2763Crossref PubMed Scopus (587) Google Scholar) found that the majority of HSCs/progenitors in the and to osteoblastic cells By they demonstrated that HSCs with have and adhesion to osteoblastic niche cells and to from the osteoblastic niche for proliferation, and differentiation A. Murphy M.J. Oskarsson T. Kaloulis K. Bettess M.D. Oser G.M. Pasche A.C. Knabenhans C. MacDonald H.R. Trumpp A. Genes Dev. 2004; 18: 2747-2763Crossref PubMed Scopus (587) Google Scholar). HSCs in the osteoblastic niche are relatively during normal homeostasis but can be as a of bone A. S. A. K. Y. M. R.M. P. A. A. T. Nat. Med. 2006; 12: PubMed Scopus Google Scholar) or Y. Battista M. Kao W.M. Hidalgo A. Cell. 2006; Full Text Full Text PDF PubMed Scopus Google Scholar). M.J. Morrison S.J. Cell Stem Cell. 2007; Full Text Full Text PDF PubMed Scopus Google Scholar) that HSCs lack however, that is by HSCs, its is when HSCs are in different found that HSCs to of can the hematopoietic in mice but with the more X. J. J. K. Cell Stem in In which function in bone remodeling, have also been shown to HSC and maintenance by osteoblasts A. S. A. K. Y. M. R.M. P. A. A. T. Nat. Med. 2006; 12: PubMed Scopus Google Scholar). However, on the of the a reduction in the number of osteoblasts may HSC function that HSCs in a for osteoblastic mouse models such as mice and mice Y. Battista M. Kao W.M. Hidalgo A. Cell. 2006; Full Text Full Text PDF PubMed Scopus Google Scholar, S. J. G.A. P. Scadden D.T. L.E. Cell. 2007; Full Text Full Text PDF PubMed Scopus Google Scholar, J.M. N.A. L.E. Orkin S.H. Cell. 2007; Full Text Full Text PDF PubMed Scopus Google Scholar) have demonstrated that reduction in trabecular bone or number HSC in a number of HSCs in BM and and extramedullary hematopoiesis in the the vascular niche is and the stage for into and In BM, some of the in the matrix of the osteoblastic niche may also be important for HSC and a matrix by is a of the HSC osteoblastic niche that the of the stem cell and may provide a mechanism for stem cell under of niche S. Y. R. C. T. E. T. D. L.M. S.R. Scadden D.T. J. Exp. Med. 2005; PubMed Scopus Google Scholar). In the high of in the BM endosteal region mediates HSC and in the osteoblastic niche by HSCs through a that is highly in HSCs G.B. Chabner K.T. Alley I.R. Olson D.P. Szczepiorkowski Z.M. Poznansky M.C. Kos C.H. Pollak M.R. Brown E.M. Scadden D.T. Nature. 2006; 439: 599-603Crossref PubMed Scopus (600) Google Scholar). endothelial cells from hematopoietic tissue more support hematopoiesis compared with endothelial cells from other H.G. Avecilla S.T. Hooper A.T. Rafii S. Physiology. 2005; 20: 349-356Crossref PubMed Scopus (414) Google Scholar, C. Z. C. H. R. B. L.A. Blood. 1998; PubMed Google Scholar, M.A. A.M. C. P. L.E. T. Mol. Cell. 2003; PubMed Scopus Google Scholar, P. J.K. 2004; 126: Full Text Full Text PDF PubMed Scopus Google Scholar). (41Kiel M.J. Yilmaz O.H. Iwashita T. Terhorst C. Morrison S.J. Cell. 2005; 121: 1109-1121Abstract Full Text Full Text PDF PubMed Scopus (2414) Google Scholar) have demonstrated that HSCs to the of in BM and spleen in mice after HSC and also to BM during The of a number of HSCs in the vascular niche that the BM and spleen provides a specific niche for proliferation, and differentiation under both and The that HSCs detach from the osteoblastic niche and the of BM to the vascular region, they hematopoiesis during hematopoietic after S.T. Hattori K. B. R. F. K. Dias S. Zhang F. Hackett N.R. Crystal R.G. L. Hicklin D.J. P. D. Lyden D. F. Rafii S. Nat. Med. 2004; PubMed Scopus Google Scholar, 53Kopp H.G. Avecilla S.T. Hooper A.T. Rafii S. Physiology. 2005; 20: 349-356Crossref PubMed Scopus (414) Google Scholar, S. R. F. Moore M.A. 1997; PubMed Scopus Google Scholar), also suggests the existence of a vascular BM HSC niche. However, the that of osteoblasts results in a reduction of HSCs in BM and extramedullary hematopoiesis (68Visnjic D. Kalajzic Z. Rowe D.W. Katavic V. Lorenzo J. Aguila H.L. Blood. 2004; 103: 3258-3264Crossref PubMed Scopus (598) Google Scholar) suggests that the vascular niche may provide a J.M. Li L. Cell. 2007; Full Text Full Text PDF PubMed Scopus Google Scholar). CXCL12 is a that cell through interaction with its which is by the cells. in including HSC in BM during the of hematopoiesis from fetal to BM, cell and cell and as demonstrated by mutant mice with disruption T. K. T. T. K. Nagasawa T. Immunity. 2003; Full Text Full Text PDF PubMed Scopus Google Scholar). important in HSC and HSC of mice (the into the that CXCL12 is by a population of stromal cells BM (42Sugiyama T. Kohara H. Noda M. Nagasawa T. Immunity. 2006; 25: 977-988Abstract Full Text Full Text PDF PubMed Scopus (1693) Google Scholar, K. T. T. B.I. Nagasawa T. Immunity. 2004; 20: Full Text Full Text PDF PubMed Scopus Google Scholar,

To systematically identify and summarize possible subtypes of complex regional pain syndrome (CRPS), we searched MEDLINE, Embase, Cochrane, Scopus, and Web of Science for original studies reporting or investigating at least one subtype within a group of patients with CRPS. The search retrieved 4239 potentially relevant references. Twenty-five studies met our inclusion criteria and were included in the analysis. Complex regional pain syndrome phenotypes were investigated based on the following variables: clinical presentation/sensory disturbances, dystonia, skin temperature, disease duration, onset type, CRPS outcome, and neuropsychological test performance. Support was found for the following CRPS subtypes: CRPS type I, CRPS type II, acute CRPS, chronic CRPS, centralized CRPS, cold CRPS, warm CRPS, inflammatory CRPS, dystonic CRPS, nondystonic CRPS, familial CRPS, and nonfamilial CRPS. It is unclear whether these are distinct or overlapping subtypes. The results of this comprehensive review can facilitate the formulation of well-defined CRPS subtypes based on presumed underlying mechanisms. Our findings provide a foundation for establishing and defining clinically meaningful CRPS subtypes, with the ultimate goal of developing targeted and enhanced treatments for CRPS.

Postural Tachycardia Syndrome from a Pediatrics Perspective

Ulnar Thumb Pulp Reconstruction Using the Anterograde Homodigital Neurovascular Island Flap.